MEDTE:PA:PA- (EUR)

ETF | Others |

Last Closing

USD 8.4456

Change

+0.03 (+0.40)%

Market Cap

N/A

Volume

120.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JPX4:PA Amundi Index Solutions - Amund..

-0.52 (-1.17%)

USD 55.57B
SPY5:PA SPDR® S&P 500 UCITS ETF EUR

N/A

USD 13.81B
SP5C:PA Lyxor S&P 500 UCITS ETF - C-EU..

+0.06 (+0.02%)

USD 12.91B
WRD:PA HSBC MSCI World UCITS ETF

-0.05 (-0.14%)

USD 11.43B
MEUD:PA Amundi Stoxx Europe 600 UCITS ..

-1.09 (-0.43%)

USD 9.42B
EQQQ:PA Invesco EQQQ NASDAQ-100 UCITS ..

+0.95 (+0.22%)

USD 8.68B
WLD:PA Lyxor UCITS MSCI World D-EUR

+0.11 (+0.03%)

USD 7.98B
HHH:PA HSBC S&P 500 UCITS ETF

-0.02 (-0.03%)

USD 7.67B
HSTE:PA HSBC ETFS PLC - HSBC Hang Seng..

-0.08 (-1.20%)

USD 6.16B
SPY4:PA SSgA SPDR S&P 400 US Mid Cap

+0.39 (+0.47%)

USD 5.54B

ETFs Containing MEDTE:PA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.24% 36% F 41% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.24% 35% F 40% F
Trailing 12 Months  
Capital Gain -3.26% 12% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.26% 12% F 36% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.51% 25% F 42% F
Dividend Return 2.51% 24% F 68% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 4.33% 86% B+ 96% N/A
Risk Adjusted Return 57.84% 38% F 79% B-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.